Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
News|Articles|April 9, 2026
ASCO Thyroid Cancer Guideline Updates Synthesize Evidence-Based Systemic Therapy Recommendations
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Kirsty Mackay
ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.
Advertisement
Advertisement
On April 1, 2026, the American Society of Clinical Oncology (ASCO) published new clinical practice guidelines with evidence-based recommendations for the use of systemic therapy across thyroid cancer subtypes.1 Read on for a snapshot of the most pertinent updates.
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Advertisement
Advertisement